The subgroup analysis of the PACIFIC study showed that the PFS benefit trend of receiving PD-L1 monoclonal antibody within 14 days after concurrent radiotherapy and chemotherapy for stage III unresectable NSCLC was more significant than that of receiving PD-L1 antibody treatment for14 days (51–53). Here, CD274 is linked to non-small cell lung carcinoma.